ClinicalTrials.gg
RecruitingNCT06403501Updated Jul 9, 2025

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

A Phase 3 interventional study of Clascoterone and Vehicle cream in Acne Vulgaris, sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
692
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Planned enrollment
3rd of 19
692 · median 50
Started
2024
with 4 others
Phase 3
5 of 19
2 open now
Registered
10th of 19
by date
Lead sponsor
3 of 19
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 3rd largest by planned enrollment, is one of 5 that started in 2024, is one of 5 in phase 3, and was the 10th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne Vulgaris
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with facial acne vulgaris (which includes the nose) from moderate to severe, has an Investigator's Global Assessment (IGA) score of 3 or 4; with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones);
  • Male or female, 12 years of age or older;
  • Subjects aged 18 years or older are required to provide and sign the written informed consent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of consent signing.

Exclusion criteria

Exclusion Criteria:

  • Subject has greater than two (2) facial nodules;
  • Subject has any skin pathology or condition that could interfere with the investigator's clinical evaluation of the drug;
  • Subject has used topical and systemic anti-acne medications or therapies;
  • Subject has received hormonal therapy for acne treatment;
  • Subject has used a skincare product with acne removal effect;
  • Subject has other serious underlying diseases such as mental illness or malignant tumors;
  • Subject has any of the laboratory test indicators at screening;
  • Subject has known or previous allergic reaction to multiple drugs, or any of the active or inactive components of the test articles;
  • Subject engaged in drug abuse or excessive alcohol intake;
  • Subject has uncontrolled hypertension; Subject has poorly controlled diabetes;
  • Subject is pregnant, lactating, or is planning to become pregnant during the study (both male and female); subject has positive pregnancy test result; subject is unable to practice highly effective methods during the trial and within 3 months after the end of the trial;
  • Subject is currently enrolled or was enrolled in other clinical trials within 3 months prior to the initiation of treatment;
  • Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
692 participants (estimated)

Study arms

  • Experimental
    Clascoterone Cream 1%

    Clascoterone Cream 1% (Winlevi)

    Drug: Clascoterone

  • Placebo comparator
    Vehicle cream

    Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.

    Drug: Vehicle cream

Interventions

  • Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

    Also known as: Winlevi (brand name)

  • DrugVehicle cream

    Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

    Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

    Time frame: Week 12

  2. Change From Baseline in Non-inflammatory Lesion (NIL) Counts

    Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

    Time frame: Week 12

  3. Change From Baseline in Inflammatory Lesion (IL) Counts

    Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Total Lesion Counts

    Absolute change from Baseline in total lesions counts in each treatment group at Week 12.

    Time frame: Week 12

  2. Percent Change From Baseline in Total Lesion Counts

    Percent change from Baseline in total lesions counts in each treatment group at Week 12.

    Time frame: Week 12

  3. Percent Change From Baseline in Inflammatory Lesion Counts

    Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.

    Time frame: Week 12

  4. Percent Change From Baseline in Non-inflammatory Lesion Counts

    Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.

    Time frame: Week 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2026, 29 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's planned 29 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 8, 2024
StartActual
May 20, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06403501
Responsible party
Sponsor
First posted
May 8, 2024
Start date
May 20, 2024
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jul 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion